Akeso's Ivonescimab Meets Primary OS Endpoint in Phase III First-Line Advanced Biliary Tract Cancer Study
nashnova research
Akeso's bispecific antibody ivonescimab met its overall survival primary endpoint in a 682-patient Phase III trial for advanced biliary tract cancer, cutting death risk by 25% versus the current standard. This means → ivonescimab is expanding beyond lung cancer into GI tumors, moving one step closer to approval.
What exactly did this trial compare?
The study, HARMONi-GI1, enrolled 682 patients with advanced biliary tract cancer. It is a Phase III registrational trial — the highest-level study that can directly support a marketing application.
It compared ivonescimab (AK112, a bispecific antibody) plus chemotherapy against durvalumab (the current standard immunotherapy) plus chemotherapy — a head-to-head test of next-gen versus the incumbent.
This means → the win was not against placebo but against the reigning champion, which makes the positive result far more convincing.
How strong are the survival numbers?
Median overall survival (OS — how long half the patients lived): ivonescimab arm 14.9 months vs durvalumab arm 12.1 months, a 25% reduction in death risk (HR = 0.75, P = 0.0031).
Median progression-free survival (PFS — time before the tumor started growing again): 8.4 months vs 5.8 months, a 39% reduction in disease-progression or death risk.
Objective response rate (ORR — share of patients whose tumors shrank significantly): 53.8% vs 32.5%, an absolute gap of 21.3 percentage points.
In plain terms = all three core metrics beat the control. In a cancer where survival is typically short, gaining nearly 3 extra months of median OS is a clinically meaningful improvement.
Any new safety concerns?
The ivonescimab arm showed a manageable safety profile. The most common adverse events were hematological toxicities such as low white-blood-cell counts, with no new safety signals detected.
Patients on ivonescimab stayed on treatment longer, indicating acceptable tolerability — no prominent pattern of early discontinuation due to toxicity.
This means → the efficacy advantage did not come at the cost of worse side effects, a key factor for regulatory review.
How close is approval?
In China, the National Medical Products Administration has provisionally granted priority review status for this indication. In plain terms = the regulatory lane just switched from standard to express.
Globally, partner Summit Therapeutics has launched a multi-center Phase II/III registrational study (EA2251) comparing ivonescimab plus chemo against pembrolizumab (Keytruda) or durvalumab plus chemo, targeting the US and European markets directly.
This reflects an accelerating global path — domestic approval on the fast track, overseas registrational studies running in parallel.
What does this mean for Akeso?
HARMONi-GI1 is the first Phase III win for ivonescimab in a GI tumor. All previous positive Phase III data came from lung cancer.
This means → ivonescimab's indication map is expanding from a single cancer type toward multiple solid tumors — the key variable the market uses to gauge an immunotherapy drug's revenue ceiling.
The next milestones to watch: whether this dataset secures approval, and whether the drug can extend into additional GI cancers. That will determine whether ivonescimab is "a good drug" or "a platform-level product."
市场有风险，内容仅供研究参考，不构成投资建议。